Technology | 2010.03.04
ProChon Biotech Nearing Midpoint of Patient Enrollment for BioCart Clinical Study
WOBURN, Mass.--(BUSINESS WIRE)--ProChon Biotech, Ltd., an innovator of tissue regenerative technologies that are being developed to relieve pain and restore the mobility and quality-of-life for sufferers of articular cartilage injuries, today announced that patient enrollment in the Company’s Phase II study of the BioCart™ Autologous Cartilage System is nearing the halfway point and is expected to be completed within the next three months. The randomized, double-arm, open-label, mult
For more information, please visit
http://www.businesswire.com/news/home/20100304005097/en
